122cc太阳集成游戏

  • Cancel
    Date：2022-01

    Exclusive Financial Advisor to Vibrant Therapeutics

  • Cancel
    Date：2022-01

    Financial Advisor to PAG

  • Cancel
    Date：2022-01
    /index.php?a=shows&catid=34&id=717

    Accro Bioscience (Suzhou) Limited, a leader in China's small molecule drug development, recently closed its Series B fundraising, raising over $50 million and surpassing its initial fundraising target. The round was led by Hongtai Aplus, with participatio

  • Cancel
    Date：2021-12
    /index.php?a=shows&catid=34&id=791

    ChosenMed successfully closed a Series C2 financing, raising several hundred million RMB from YiJing Capital, with participation from Linzhuo Industry Fund and other leading institutions. CEC Capital Group served as the exclusive financial advisor in

  • Cancel
    Date：2021-12
    /index.php?a=shows&catid=34&id=792

    SyMap Medical recently announced the successful financing of nearly $100 million from VMS Group and Primavera Capital, with participation from SiMiao Capital and HongShan Capital. CEC Capital Group served as the exclusive financial advisor in this tra

  • Cancel
    Date：2021-11
    /index.php?a=shows&catid=34&id=793

    Brain Doctor Group (BDG), China's first physician group to establish a specialized brain hospital, announced today the closing of a RMB 200 million Series C financing. Led by Sequoia China, t

  • Cancel
    Date：2021-11
    /index.php?a=shows&catid=34&id=795

    Beijing Changmugu Medical Technology Co., Ltd. (referred to as 'Changmugu'), a leading provider of integrated intelligent surgical solutions for orthopedics, announced the closing of a RMB 540 million Series B financing. The funding was jointly led by CIC

  • Cancel
    Date：2021-10
    /index.php?a=shows&catid=34&id=796

    Beijing Bio-Bank Corporation ("Bio-Bank"), a biopharmaceutical company specializing in large molecule drug development, announced the successful closing of a hundred million RMB Series A financing, led by CDH Investments. CEC Capital served as the exclus

  • Cancel
    Date：2021-10
    /index.php?a=shows&catid=34&id=797

    Shanghai BiOligo Biotech Co., Ltd. (referred to as "BiOligo"), a leading supplier of in vitro diagnostics and nucleic acid drug raw materials, recently closed a RMB 300 million Series A financing. The funding was led by The Carlyle Group, a global leading


【网站地图】【sitemap】